Sustained reduction of MS disability: New player in comparing disease-modifying treatments

Bibiana Bielekova¹, Mar Tintore²

• ¹From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. Bibi.Bielekova@nih.gov.+1